

Corrections

tyrp1-TAG/*tyrp1*-FGFR1-DN Bigenic Mouse

In the article on the *tyrp1*-TAG/*tyrp1*-FGFR1-DN bigenic mouse in the April 1, 2004 issue of *Cancer Research* (1), there should have been a note stating that B. Rousseau and F. Larrieu-Lahargue contributed equally to that work.

1. Rousseau B, Larrieu-Lahargue F, Javerzat S, Guilhem-Ducléon F, Beermann F, Bikfalvi A. The *tyrp1*-TAG/*tyrp1*-FGFR1-DN bigenic mouse: A model for selective inhibition of tumor development, angiogenesis, and invasion into the neural tissue by blockade of fibroblast growth factor receptor activity. *Cancer Res* 2004;64:2490–5.

Correspondence re R. Lapointe *et al.*

In the letter to the editor regarding the article by R. Lapointe *et al.*, CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells, in the June 1, 2004 issue of *Cancer Research* (1), the order of the authors of the letter was incorrect. The order of the authors should be M. von Bergwelt-Baildon, B. Maecker, I. Menezes, L. M. Nadler, and J. L. Schultze.

1. von Bergwelt-Baildon M, Maecker B, Menezes I, Nadler LM, Schultze JL. Correspondence re R. Lapointe *et al.*, CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells. *Cancer Res* 2004;64:4055–7.

CLIP Expression on Myeloid Leukemia Blasts

In the article on CLIP Expression on Myeloid Leukemic Blasts in the August 15, 2004 issue of *Cancer Research* (1), the affiliation for S. Marieke van Ham is incorrect. The affiliation should have read the Department of Pathology, VU University Medical Center, Amsterdam, the Netherlands and the Department of Immunopathology, Sanguin Research at Central Laboratory of The Netherlands Red Cross Blood Transfusion Service, Amsterdam, the Netherlands.

1. Chamuleau MED, Souwer Y, Marieke van Ham S, Zevenbergen A, Westers TM, Berkhof J, Meijer CJLM, van de Loosdrecht AA, and Osenkuppele GJ: Class II-associated invariant chain peptide expression on myeloid leukemic blasts predicts poor clinical outcome. *Cancer Res* 2004;64:5546–50.